My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 359

    1.

    The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

    Golan L, Birkmeyer JD, Welch HG.

    Ann Intern Med. 1999 Nov 2;131(9):660-7.PMID: 10577328 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

    Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

    Ann Intern Med. 2005 Jul 19;143(2):89-99.PMID: 16027450 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.

    Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S.

    CMAJ. 2000 Jan 25;162(2):195-8. Erratum in: CMAJ 2000 Apr 4;162(7):973. PMID: 10674051 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?

    Kiberd BA, Jindal KK.

    Mayo Clin Proc. 1999 Jun;74(6):559-64.PMID: 10377929 [PubMed - indexed for MEDLINE]Related articles

    5.

    Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

    Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM.

    Pharmacoeconomics. 2004;22(15):1015-27.PMID: 15449965 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

    CDC Diabetes Cost-effectiveness Group.

    JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Screening for proteinuria in US adults: a cost-effectiveness analysis.

    Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR.

    JAMA. 2003 Dec 17;290(23):3101-14.PMID: 14679273 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ.

    Nephrol Dial Transplant. 2003 Oct;18(10):2059-66.PMID: 13679481 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation.

    Kiberd BA, Jindal KK.

    BMJ. 1995 Dec 16;311(7020):1595-9.PMID: 8555801 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation.

    Kiberd BA, Jindal KK.

    Am J Kidney Dis. 1998 Jan;31(1):49-54.PMID: 9428451 [PubMed - indexed for MEDLINE]Related articles

    11.

    An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.

    Rodby RA, Firth LM, Lewis EJ.

    Diabetes Care. 1996 Oct;19(10):1051-61.PMID: 8886549 [PubMed - indexed for MEDLINE]Related articles

    12.

    Systematic review on urine albumin testing for early detection of diabetic complications.

    Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

    Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.PMID: 16095545 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus.

    Siegel JE, Krolewski AS, Warram JH, Weinstein MC.

    J Am Soc Nephrol. 1992 Oct;3(4 Suppl):S111-9.PMID: 1457753 [PubMed - indexed for MEDLINE]Related articles

    14.

    Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria.

    Smith DG, Nguyen AB, Peak CN, Frech FH.

    J Manag Care Pharm. 2004 Jan-Feb;10(1):26-32.PMID: 14720103 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    [Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients]

    Gozzoli V, Palmer AJ, Brandt A, Weiss C, Piehlmeier W, Landgraf R, Renner R.

    Dtsch Med Wochenschr. 2000 Sep 29;125(39):1154-9. German. PMID: 11075242 [PubMed - indexed for MEDLINE]Related articles

    16.

    A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

    Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

    Curr Med Res Opin. 2006 Nov;22(11):2095-100.PMID: 17076969 [PubMed - indexed for MEDLINE]Related articles

    17.

    WITHDRAWN: Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.

    Lovell HG.

    Cochrane Database Syst Rev. 2007 Jul 18;(1):CD002183. Review.PMID: 17636698 [PubMed - indexed for MEDLINE]Related articles

    18.

    A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy.

    Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN.

    J Clin Hypertens (Greenwich). 2007 Oct;9(10):751-9.PMID: 17917502 [PubMed - indexed for MEDLINE]Related articles

    19.

    Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.

    Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, Postma MJ.

    Pharmacogenet Genomics. 2009 Sep;19(9):695-703.PMID: 19696696 [PubMed - indexed for MEDLINE]Related articles

    20.

    Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.

    Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL.

    Pharmacogenet Genomics. 2007 May;17(5):359-68.PMID: 17429318 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity